UBS Maintains Buy on Viatris, Raises Price Target to $26

UBS analyst Ashwani Verma has maintained a 'Buy' rating on Viatris (NASDAQ: VTRS) and increased the price target from $23 to $26. This adjustment reflects a positive outlook for the company's stock performance.